Major Depressive Disorder Clinical Trial
Official title:
A Phase 2/3 Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of PRAX-114 in Participants With Major Depressive Disorder
Verified date | July 2022 |
Source | Praxis Precision Medicines |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a randomized, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of PRAX-114 in participants with moderate to severe major depressive disorder (MDD). Participants will be randomized to receive 28 days of either 40 mg PRAX-114 or placebo in a 1:1 ratio.
Status | Completed |
Enrollment | 216 |
Est. completion date | May 5, 2022 |
Est. primary completion date | May 5, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: 1. Recurrent MDD diagnosis with a current episode duration of at least 8 weeks and no more than 24 months. 2. HAM-D17 total score of =23 at Screening and Baseline. 3. Body mass index (BMI) between 18 and 38 kg/m2 (inclusive). Exclusion Criteria: 1. Lifetime history of seizures, including febrile seizures. 2. Neurodegenerative disorder (eg, Alzheimer's disease, Parkinson's disease, multiple sclerosis, or Huntington's disease). 3. Lifetime history of bipolar disorder, a psychotic disorder (eg, schizophrenia or schizoaffective disorder), or obsessive compulsive disorder or a history of a psychotic mood episode in last 2 years. 4. Any current psychiatric disorder (other than MDD). 5. Lifetime history of treatment resistant depression. 6. Received electroconvulsive therapy (ECT) or vagus nerve stimulation (VNS) within the last year or transcranial magnetic stimulation (TMS) within the last 6 months prior to Screening. 7. Daily consumption of more than 2 standard alcohol-containing beverages for males or more than 1 standard alcohol-containing beverages for females. |
Country | Name | City | State |
---|---|---|---|
Australia | Praxis Research Site | Noble Park | Victoria |
United States | Praxis Research Site | Allentown | Pennsylvania |
United States | Praxis Research Site | Atlanta | Georgia |
United States | Praxis Research Site | Austin | Texas |
United States | Praxis Research Site | Berlin | New Jersey |
United States | Praxis Research Site | Cedarhurst | New York |
United States | Praxis Research Site | Charlottesville | Virginia |
United States | Praxis Research Site | Chicago | Illinois |
United States | Praxis Research Site | Dayton | Ohio |
United States | Praxis Research Site | Decatur | Georgia |
United States | Praxis Research Site | Everett | Washington |
United States | Praxis Research Site | Gaithersburg | Maryland |
United States | Praxis Research Site | Garden Grove | California |
United States | Praxis Research Site | Jacksonville | Florida |
United States | Praxis Research Site | Lafayette | California |
United States | Praxis Research Site | Las Vegas | Nevada |
United States | Praxis Research Site | Lemon Grove | California |
United States | Praxis Research Site | Marlton | New Jersey |
United States | Praxis Research Site | Media | Pennsylvania |
United States | Praxis Research Site | Memphis | Tennessee |
United States | Praxis Research Site | O'Fallon | Missouri |
United States | Praxis Research Site | Oceanside | California |
United States | Praxis Research Site | Orange City | Florida |
United States | Praxis Research Site | Orlando | Florida |
United States | Praxis Research Site | Phoenix | Arizona |
United States | Praxis Research Site | Pico Rivera | California |
United States | Praxis Research Site | Redlands | California |
United States | Praxis Research Site | Rochester | New York |
United States | Praxis Research Site | San Antonio | Texas |
United States | Praxis Research Site | Staten Island | New York |
United States | Praxis Research Site | Worcester | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Praxis Precision Medicines |
United States, Australia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from baseline in 17-Item Hamilton Depression Rating Scale (HAM-D17) total score at Day 15 | The HAM-D17 is a depression rating scale consisting of 17 items; 9 items are scored on a 5-point scale (ranging from 0 to 4), and 8 items are scored on a 3-point scale (ranging from 0 to 2). The total score of the 17 items ranges from 0 to 52 with higher scores indicating greater depression. Therefore, a decrease in the total score or on individual item scores indicates improvement. | 15 days | |
Secondary | Change from baseline in HAM-D17 total score at Day 29 | The HAM-D17 is a depression rating scale consisting of 17 items; 9 items are scored on a 5-point scale (ranging from 0 to 4), and 8 items are scored on a 3-point scale (ranging from 0 to 2). The total score of the 17 items ranges from 0 to 52 with higher scores indicating greater depression. Therefore, a decrease in the total score or on individual item scores indicates improvement. | 29 days | |
Secondary | Change from baseline in HAM-D17 total score at all other time points | The HAM-D17 is a depression rating scale consisting of 17 items; 9 items are scored on a 5-point scale (ranging from 0 to 4), and 8 items are scored on a 3-point scale (ranging from 0 to 2). The total score of the 17 items ranges from 0 to 52 with higher scores indicating greater depression. Therefore, a decrease in the total score or on individual item scores indicates improvement. | 8 days, 22 days, 36 days, and 43 days | |
Secondary | Change from baseline in Clinical Global Impression-Severity (CGI-S) score at Day 15 and all other time points | The CGI-S assesses the clinician's impression of the participant's current depression symptoms. The clinician should use his/her total clinical experience with this patient population and rate the current severity of the participant's mental illness on a 7-point scale from 1 (Normal, not at all ill) to 7 (Among the most extremely ill patients). | 8 days, 15 days, 22 days, 29 days, 36 days, and 43 days | |
Secondary | Clinical Global Impression-Improvement (CGI-I) score at Day 15 and all other time points | The CGI-I assesses the participant's improvement (or worsening). The clinician is required to assess the participant's condition relative to Baseline (Day 1) on a 7-point scale from 1 (Very much improved) to 7 (Very much worse). | 8 days, 15 days, 22 days, 29 days, 36 days, and 43 days | |
Secondary | HAM-D17 response (reduction from baseline score of =50%) at Day 15, Day 29, and all other time points | The HAM-D17 is a depression rating scale consisting of 17 items; 9 items are scored on a 5-point scale (ranging from 0 to 4), and 8 items are scored on a 3-point scale (ranging from 0 to 2). The total score of the 17 items ranges from 0 to 52 with higher scores indicating greater depression. Therefore, a decrease in the total score or on individual item scores indicates improvement. | 8 days, 15 days, 22 days, 29 days, 36 days, and 43 days | |
Secondary | HAM-D17 remission (total score of =7) at Day 15, Day 29, and all other time points | The HAM-D17 is a depression rating scale consisting of 17 items; 9 items are scored on a 5-point scale (ranging from 0 to 4), and 8 items are scored on a 3-point scale (ranging from 0 to 2). The total score of the 17 items ranges from 0 to 52 with higher scores indicating greater depression. Therefore, a decrease in the total score or on individual item scores indicates improvement. | 8 days, 15 days, 22 days, 29 days, 36 days, and 43 days | |
Secondary | Change from baseline in the Symptoms of Depression Questionnaire (SDQ) total and sub-scale scores at Day 15 and all other time points | The SDQ is a 44-item, self-report scale assessing the severity of symptoms across several subtypes of depression. Items are scored on a 7-point scale (ranging from 1 to 6). The SDQ total score is the sum of all 44 item scores and ranges from 44 to 264 with higher scores indicating worse symptoms. | 8 days, 15 days, 22 days, 29 days, 36 days, and 43 days | |
Secondary | Patient Global Impression-Improvement (PGI-I) score at Day 15 and all other time points | The PGI-I scale is a global self-assessment used to rate the response of a participant's condition to therapy or intervention. It consists of 1 question that asks the participant to rate their current condition compared to how it was prior to beginning treatment on a scale of 1 (very much better) to 7 (very much worse). | 8 days, 15 days, 22 days, 29 days, 36 days, and 43 days | |
Secondary | Change from baseline in the Work and Social Adjustment Scale (WSAS) at Day 15 and all other time points | The WSAS assesses the degree to which mental health problems interfere with day-to-day functioning in 5 domains: work, social leisure activities, private leisure activities, home- management, and personal relationships. The WSAS total score is the sum of the 5 item scores and ranges from 0 to 40, with higher scores indicating poorer adjustment. | 8 days, 15 days, 22 days, 29 days, 36 days, and 43 days | |
Secondary | Change from baseline in the 12-Item Short Form Survey (SF-12) at Day 15 and all other time points | The SF-12 is composed of 12 questions covering 8 dimensions of health: Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional and Mental Health. Total scores range from 0 (worse health) to 100 (better health). | 8 days, 15 days, 22 days, 29 days, 36 days, and 43 days | |
Secondary | Incidence and severity of Adverse Events (AE) | An AE is any untoward medical occurrence in a clinical trial participant, temporally associated with the use of study drug, whether or not considered related to the study drug. | 43 days | |
Secondary | Incidence of AEs by preferred term | The incidence of AEs will be reported by preferred term, including any terms related to clinically significant changes in body temperature, pulse rate, respiratory rate, blood pressure (systolic and diastolic), clinical laboratory measures (chemistry, hematology, urinalysis, and coagulation), and electrocardiogram parameters (heart rate, PR, QRS, QT, and corrected QT intervals). | Up to 43 days | |
Secondary | Incidence of Columbia-Suicide Severity Rating Scale (C-SSRS) measured suicidal ideation or behavior | The C-SSRS is composed of 5 yes/no questions addressing suicidal behavior and 5 yes/no questions addressing suicidal ideation, with sub-questions assessing the severity. Incidence is measured as the number of "yes" answers indicating the presence of suicidal ideation or behavior. | Up to 43 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05537558 -
Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
|
||
Terminated |
NCT02192099 -
Open Label Extension for GLYX13-C-202, NCT01684163
|
Phase 2 | |
Completed |
NCT03142919 -
Lipopolysaccharide (LPS) Challenge in Depression
|
Phase 2 | |
Recruiting |
NCT05547035 -
Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders
|
N/A | |
Terminated |
NCT02940769 -
Neurobiological Effects of Light on MDD
|
N/A | |
Recruiting |
NCT05892744 -
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
|
Phase 4 | |
Recruiting |
NCT05537584 -
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
|
Phase 4 | |
Active, not recruiting |
NCT05061706 -
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT04479852 -
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
|
Phase 2 | |
Recruiting |
NCT04032301 -
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
|
Phase 1 | |
Recruiting |
NCT05527951 -
Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study
|
N/A | |
Completed |
NCT03511599 -
Cycloserine rTMS Plasticity Augmentation in Depression
|
Phase 1 | |
Recruiting |
NCT04392947 -
Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation
|
N/A | |
Recruiting |
NCT05895747 -
5-HTP and Creatine for Depression R33 Phase
|
Phase 2 | |
Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
Recruiting |
NCT05813093 -
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
|
N/A | |
Recruiting |
NCT05135897 -
The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
|
||
Enrolling by invitation |
NCT04509102 -
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
|
Early Phase 1 | |
Recruiting |
NCT06026917 -
Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
|
Phase 4 | |
Recruiting |
NCT06145594 -
EMA-Guided Maintenance TMS for Depression
|
N/A |